CSL (OTCMKTS:CSLLY) Rating Lowered to “Hold” at Royal Bank Of Canada

CSL (OTCMKTS:CSLLY) was downgraded by stock analysts at Royal Bank Of Canada from a “moderate buy” rating to a “hold” rating in a research report issued to clients and investors on Wednesday,Zacks.com reports.

CSLLY has been the subject of several other research reports. Canaccord Genuity Group upgraded CSL from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, October 28th. Zacks Research upgraded CSL from a “strong sell” rating to a “hold” rating in a report on Monday, December 29th. One equities research analyst has rated the stock with a Strong Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy”.

CSL Price Performance

Shares of OTCMKTS:CSLLY opened at $54.09 on Wednesday. The firm has a fifty day simple moving average of $59.83 and a two-hundred day simple moving average of $65.65. CSL has a 52 week low of $52.00 and a 52 week high of $89.71. The company has a debt-to-equity ratio of 0.50, a current ratio of 2.46 and a quick ratio of 1.12.

CSL Company Profile

CSL Limited (OTCMKTS: CSLLY) is a global biotechnology company headquartered in Melbourne, Australia that develops, manufactures and delivers a range of plasma-derived and recombinant therapeutics, vaccines and related services. Its principal businesses include CSL Behring, which focuses on specialty biotherapies for bleeding disorders, immune deficiencies, hereditary angioedema and other serious conditions; Seqirus, an influenza vaccine company formed following CSL’s acquisition of Novartis’ influenza vaccine business; and CSL Plasma, a network of plasma collection centers that supplies the raw material for many of its therapies.

The company’s product portfolio spans immunoglobulins, clotting factor concentrates, albumin and other protein-based treatments used in the management of chronic and acute rare diseases, as well as seasonal and pandemic influenza vaccines.